2013 UALC
Emily Cheng, MD, PhD
Memorial Sloan Kettering Cancer Center
Research Project:
Targeting the BCL-2 Family in Small Cell Lung Cancer
Summary:
Small cell lung cancer (SCLC) represents 15% of all lung cancer cases, affecting approximately 30,000 people annually in the United States. The prognosis for patients with SCLC is poor, with only 5% of patients surviving five years, and there has been little change to treatment in 30 years. Dr. Cheng is developing a new treatment for SCLC, targeting the BCL-2 family of genes. She will be performing preclinical studies of a new drug combination in patient-derived cell lines and other preclinical models.